TAGERWILEN, SWITZERLAND – October, 2008 /PRAvenueNW/ – Ethos, the Swiss based pharmaceutical company that made the headlines back in 2003 with their ‘miracle eye drops’ that dissolve cataracts naturally without the need for invasive surgery ( www.ethos.ag ) and again in 2006 with their ‘miracle anti-aging face cream’ (www.rejuvion.com) have now made an incredible breakthrough for Parkinson’s Disease sufferers the world over.Finally, they have made a revolutionary new breakthrough in the treatment of Parkinson’s Disease. Ethos Endymion PD Ease is not some new wonder drug but is an all natural substance found within all of our bodies that depletes with age. Ethos Endymion PD Ease is the purest form of this natural substance found anywhere in the world and is also certified as ‘bio-active’ by Professor Gallant and Professor Boldyrev who are the world leading authorities on this compound and who we have to thank for proving the beneficial effects it gives Parkinson’s Disease sufferers through their latest clinical trial. Not all people with Parkinson’s have a hard time doing things most of us take for granted such as being able to walk and use our hands. With Parkinson’s disease, daily life becomes first laborious, then impossible. Possibly even more debilitating, Parkinson’s disease gradually deteriorates brain cells, so that thinking becomes more and more scrambled.
Ethos Endymion PD Ease crosses the blood-brain barrier where it goes to work repairing damage at a cellular level, which in turn helps to relieve the symptoms of Parkinson’s Disease. To read a personal testimonial and a much more detailed and technical explanation, please review the Ethos PD Ease website: www.pdease.com
Google co-founder, Sergey Brin is getting a lot of attention for revealing that he is genetically pre-disposed to getting Parkinson’s Disease. Brin let his wife test his DNA and found out about the Parkinson’s link. He writes, “I know early in my life something I am substantially predisposed to. I now have the opportunity to adjust my life to reduce those odds (e.g. there is evidence that exercise may be protective against Parkinson’s). I also have the opportunity to
perform and support research into this disease long before it may affect me.”
If Ethos and Brin can strike up an alliance it will make a very powerful combination. Between them, they will be able to step up to commercial scale production with their new novel compound derivative drugs that will turn up the effects still further and help literally millions of sufferers world wide to enjoy a far better quality of life.
In the meantime, Ethos Endymion PD Ease will give sufferers today dramatic improvements. To read complete clinical trial papers, visit our website at: www.pdease.com
Ethos World GmbH Schweiz
Swiss Tel: +41 71 669 1440
UK Tel: (+44) 01462 44 11 33
USA Tel: +1 951-723-4006